ABP 980: promising trastuzumab biosimilar for HER2-positive breast cancer
Sign Up to like & getrecommendations! Published in 2018 at "Expert Opinion on Biological Therapy"
DOI: 10.1080/14712598.2018.1430761
Abstract: ABSTRACT Introduction: Approval of the HER2-targeted antibody trastuzumab dramatically improved outcomes for patients with HER2-positive breast cancer. Multiple trastuzumab biosimilars, including ABP 980, are in clinical development. Biosimilars are not identical to the reference biologic,… read more here.
Keywords: abp 980; trastuzumab; trastuzumab biosimilar; breast cancer ... See more keywords
P05 Cardiac safety of the trastuzumab biosimilar ABP 980 in women with HER2-positive early breast cancer in the LILAC study
Sign Up to like & getrecommendations! Published in 2019 at "International Journal of Gynecological Cancer"
DOI: 10.1136/ijgc-2019-esgo.70
Abstract: Introduction/Background Although well-tolerated, trastuzumab can lead to severe heart failure in 2–4% of patients. In the phase 3 LILAC trial, trastuzumab biosimilar ABP 980 demonstrated similar efficacy, safety, and immunogenicity to trastuzumab reference product (RP)… read more here.
Keywords: cardiac safety; amgen; safety; abp 980 ... See more keywords
Cardiac safety of the trastuzumab biosimilar ABP 980 in women with HER2-positive early breast cancer in the LILAC study.
Sign Up to like & getrecommendations! Published in 2019 at "Journal of Clinical Oncology"
DOI: 10.1200/jco.2019.37.15_suppl.557
Abstract: 557 Background: Although trastuzumab is generally well-tolerated, cardiotoxicity is the main limitation in its use, leading to a severe heart failure in 2-4% of patients in adjuvant trials. In the phase 3 LILAC trial, trastuzumab… read more here.
Keywords: cardiac safety; trastuzumab biosimilar; abp 980; safety ... See more keywords